-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Underweight on Veracyte, Lowers Price Target to $44

Benzinga·08/04/2026 12:42:55
語音播報
Morgan Stanley analyst Tejas Savant maintains Veracyte (NASDAQ:VCYT) with a Underweight and lowers the price target from $47 to $44.